Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Thousands Of Pennsylvania Graduates Need Health Insurance Options
Employers will hire 22 percent fewer college graduates in 2009 than they did last year, according to the National Association of Colleges and Employers. That means thousands of Pennsylvania college students graduating this spring may be without health insurance coverage due to unemployment or time elapsing before starting a new job.
generic viagra online
Final Analysis Shows HPV Vaccine Highly Effective At Preventing Precancerous Cervical Lesions
The final analysis of the PATRICIA study shows that the HPV-16/18 AS04-adjuvanted vaccine (GlaxoSmithKline) has high efficacy against the precancerous cervical lesions that can eventually lead to cervical cancer. The vaccine also shows cross-protective efficacy against other oncogenic (cancer-causing) HPV types closely related to HPV-16/18. Furthermore, it also shows efficacy in the cohorts relevant to universal mass vaccination and catch-up programmes. The findings are reported in an Article Online First and in an upcoming edition of The Lancet, written by Dr Jorma Paavonen, University of Helsinki, Finland, and colleagues.
News of the day
PET Can Help Guide Treatment Decisions For A Common Pediatric Cancer
A new study published in the August issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) is an important tool for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease. Neuroblastoma accounts for six to ten percent of all childhood cancers in the United States and 15 percent of cancer deaths in children. Accurately identifying where in the body the disease is located and whether it is spreading is critical for choosing appropriate types of treatment, which can include surgery, chemotherapy, radiation and-in the most advanced cases-a combination of all of these treatments along with bone marrow transplant or investigational therapies.
Sexual Health

University Of Pittsburgh Cancer Institute Researcher Dr. Merrill Egorin Honored With ASCO Translational Research Professorship

Merrill Egorin, M.D., professor of medicine and pharmacology at the University of Pittsburgh Cancer Institute (UPCI), has received the 2009 American Society of Clinical Oncology (ASCO) Translational Research Professorship for his work in improving cancer treatments and supporting the next generation of researchers. The award provides $100,000 annually for five years to further the training and career development of clinical oncologists for whom translational research is the primary or major component of their professional activities. "I am tremendously honored to receive this wonderful award, which truly encourages bench-to-bedside research," said Dr. Egorin. "I"ve dedicated my career to pursuing translational research and having my efforts recognized by ASCO is both humbling and inspiring." "This award acknowledges Dr. Egorin"s lifelong dedication to improving cancer treatments and rewards his ongoing and passionate commitment to mentoring the next generation of researcher," said Nancy E. Davidson, M.D., director of UPCI and UPMC Cancer Centers. "One of the most important responsibilities for accomplished researchers is the nurturing and support of junior investigators, and no one has been more engaged in this process than Dr. Egorin." Dr. Egorin will use the professorship to continue his pre-clinical and clinical studies of inhibitors of the PARP family of enzymes and how they can be exploited as targets for cancer therapies. PARP enzymes are responsible for a variety of cellular processes, including gene regulation, replication and the maintenance of genomic stability. "The PARP family is an extremely interesting target for drug development. We already have several PARP inhibitors in early development, including several phase I trials evaluating the drug ABT-888. This award will support the expansion of the study of PARP inhibitors in cancer treatments," he said. Dr. Egorin will officially receive his award on May 31 during ASCO"s Grants and Awards ceremony. The University of Pittsburgh Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009